Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.
暂无分享,去创建一个
A. Vortmeyer | R. Herbst | A. Chiang | S. Gettinger | M. Sznol | H. Kluger | A. Tsiouris | U. Hegde | James B. Yu | A. Mahajan | L. Jilaveanu | A. Ralabate | Lucia B. Jilaveanu | A. Rivera | X. Yao | V. Chiang | Justine V. Cohen | S. Goldberg | Stephanie Speaker | Matthew Madura | E. Rowen | H. Gerrish | J. Cohen | Xiaopan Yao
[1] A. Vortmeyer,et al. Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment , 2015, Cancer Immunology Research.
[2] H. Kluger,et al. Clinical trials in melanoma patients with brain metastases , 2015, Pigment cell & melanoma research.
[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[4] Wei Zhou,et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. , 2015, The Lancet. Oncology.
[5] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[6] J. Larkin,et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.
[7] Lucio Crinò,et al. Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Lunceford,et al. Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.
[9] D. Schadendorf,et al. Nivolumab in previously untreated melanoma without BRAF mutation. , 2015, The New England journal of medicine.
[10] Andreas Rimner,et al. Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.
[11] A. Vortmeyer,et al. Radiologic and histologic consequences of radiosurgery for brain tumors , 2014, Journal of Neuro-Oncology.
[12] H. Kluger,et al. Advances in therapy for melanoma brain metastases. , 2013, Clinics in dermatology.
[13] Yi-long Wu,et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] A. Hauschild,et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[15] M. Robbins,et al. Radiation-induced cognitive impairment--from bench to bedside. , 2012, Neuro-oncology.
[16] P. Ascierto,et al. Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. , 2012, The Lancet. Oncology.
[17] J. Villano,et al. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. , 2012, Neuro-oncology.
[18] J. Wolchok,et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.
[19] F. Barlesi,et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] S. Ariyan,et al. Melanoma brain metastases: is it time to reassess the bias? , 2011, Current problems in cancer.
[21] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[22] R. Talamini,et al. Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. , 2010, Lung cancer.
[23] A. Sloan,et al. Diagnosis and treatment of melanoma brain metastasis: a literature review. , 2009, Cancer control : journal of the Moffitt Cancer Center.
[24] J. Knisely,et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. , 2008, Journal of neurosurgery.
[25] D. Kondziolka,et al. Gamma knife radiosurgery for malignant melanoma brain metastases. , 2006, Clinical neurosurgery.
[26] J. Posner,et al. Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.
[27] M. McDermott,et al. Gamma knife radiosurgery for malignant melanoma brain metastases. , 1998, The cancer journal from Scientific American.
[28] H. Hansen,et al. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] A. Gershuny,et al. Central nervous system lnvolvement in malignant melanoma , 1988 .
[30] G. Hutchins,et al. Patterned distribution of metastases from malignant melanoma in humans. , 1983, Cancer research.
[31] A. Dicker,et al. On the merits and limitations of whole-brain radiation therapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.